Tamir Biotechnology, Inc. Form 4

July 25, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or

Form 5

obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

Tamir Biotechnology, Inc. [ACEL]

(Print or Type Responses)

(Last)

MONMOUTH

(City)

1. Title of

Security (Instr. 3)

JUNCTION, NJ 08852

1. Name and Address of Reporting Person * **BRANCACCIO JOHN P**

(First) (Middle)

C/O TAMIR BIOTECHNOLOGY. INC., 11 DEER PARK DRIVE,

SUITE 204

(Street)

(State)

(Month/Day/Year)

(Zip)

2. Transaction Date 2A. Deemed

Filed(Month/Day/Year)

(Month/Day/Year)

07/23/2012

Symbol

4. If Amendment, Date Original

3. Date of Earliest Transaction

3. 4. Securities

Execution Date, if TransactionAcquired (A) or Code Disposed of (D) (Instr. 8) (Instr. 3, 4 and 5)

(Month/Day/Year)

(A) or

Code V Amount (D) Price

OMB

Number:

Expires:

response...

Estimated average

burden hours per

OMB APPROVAL

3235-0287

January 31,

2005

0.5

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

X_ Director 10% Owner

Officer (give title Other (specify below)

6. Individual or Joint/Group Filing(Check

Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

5. Amount of 6. Ownership 7. Nature of Securities Form: Direct Indirect Beneficially (D) or Indirect Beneficial Owned Ownership (I) Following (Instr. 4) (Instr. 4)

Reported Transaction(s) (Instr. 3 and 4)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

SEC 1474 (9-02)

1

Edgar Filing: Tamir Biotechnology, Inc. - Form 4

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	ion (Month/Day/Year) Execution Date, if TransactionDerivative any Code Securities (Month/Day/Year) (Instr. 8) Acquired ve		5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and	D)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		
	Security			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount Number Shares
Common Stock (Right to Buy) (1)	\$ 0.04	07/23/2012		A	375,000	12/31/2012	12/31/2017	Common Stock	375,00

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

BRANCACCIO JOHN P C/O TAMIR BIOTECHNOLOGY, INC. 11 DEER PARK DRIVE, SUITE 204 MONMOUTH JUNCTION, NJ 08852



Signatures

/s/ John P.

Brancaccio 07/25/2012

**Signature of Date Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Issued under the Company's 2004 Stock Incentive Plan and qualified under Rule 16b-3(d).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2